Accelerant Holdings (ARX) is an innovative specialty insurance and reinsurance provider committed to serving underserved markets with a collaborative membership model. Utilizing advanced data analytics and cutting-edge technology, the company enhances underwriting performance and fosters innovation in risk management alongside its insurance partners. This strategic framework allows Accelerant to agilely adapt to the evolving insurance landscape, thereby positioning itself for sustained long-term growth anchored in operational excellence.
| Revenue (TTM) | $1.07B |
| Gross Profit (TTM) | $697.30M |
| EBITDA | $109.40M |
| Operating Margin | 15.60% |
| Return on Equity | -222.00% |
| Return on Assets | 0.54% |
| Revenue/Share (TTM) | $4.93 |
| Book Value | $3.31 |
| Price-to-Book | 5.99 |
| Price-to-Sales (TTM) | 4.00 |
| EV/Revenue | 2.404 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 800.00% |
| Quarterly Revenue Growth (YoY) | 57.20% |
| Shares Outstanding | $118.55M |
| Float | $56.79M |
| % Insiders | 48.74% |
| % Institutions | 59.76% |
Volatility is currently expanding
NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a law firm representing investors in securities and corporate governance matters, is investigating the proposed sale of Accelerant Holdings (NYSE: ARX) to private equity firm Thoma Bravo for $20.25 per share.
Accelerant Holdings NYSE: ARX jumped into view for investors in mid-August after its shares surged 43% in a single day. This type of share price leap is often reserved for clinical-stage biotech firms announcing breakthrough results, for instance, not for an unglamorous firm connecting specialty insurance risk across a network of capital providers.
Accelerant Holdings (ARX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ARX's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
ARX is going private just over a year after its IPO, as Thoma Bravo's $4 billion deal capitalizes on stronger operating results.
ARX's Q2 earnings beat estimates as premium growth, higher fee revenues and stronger Exchange Services drive results.
MILWAUKEE, Aug. 13, 2026 /PRNewswire/ -- Ademi LLP is investigating Accelerant (NYSE: ARX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Thoma Bravo. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
The headline numbers for Accelerant Holdings (ARX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
U.S. stocks were higher, with the Nasdaq Composite gaining around 200 points on Thursday.
Accelerant Holdings (ARX) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.14 per share a year ago.
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a law firm representing investors in securities and corporate governance matters, is investigating the proposed sale of Accelerant Holdings (NYSE: ARX) to private equity firm Thoma Bravo for $20.25 per share. The investigation focuses on the fairness of the transaction to Accelerant's public shareholders and potential conflicts arising from the participation of Altamont Capital Partners (“ACP”), Accelerant's controlling shareholder.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ARX and any ticker you trade — then tracks every position and per-strategy win rate.
